Navigation Links
Inspiro Medical Ltd. Completes a Successful First Clinical Trial in Asthmatic Children

TEL AVIV, Israel, June 6, 2013 /PRNewswire/ --

Inspiro Medical, a portfolio company of The Trendlines Group, recently completed a successful clinical trial for InspiromaticTM, its innovative, breath-synchronized, active dry powder inhaler.

The study, completed in May 2013 at Schneider Medical Center aimed to objectively assess, in a randomized, crossover, double blind study, the efficacy and safety profiles of formoterol (bronchodilator) treatment via the Inspiromatic in asthmatic children, compared to its delivery via a competitive inhaler already on the market.

30 children with asthma, aged 8-18, were randomly allocated to treatment with formoterol via the Inspiromatic inhaler or a competitive device.

The study met both primary and secondary endpoints. The results demonstrated superior results for of the Inspiromatic in pulmonary delivery of the active drug. Lung function test (FEV1) demonstrated a statistically significant improvement following formoterol delivery via the Inspiromatic. Moreover, the Inspiromatic was highly rated by patients. Successful delivery of the API was achieved even with patients with poor inhalation technique and even in low-flow inhalation rate.  

"I'm very happy with the study results showing that the Inspiromatic achieved safety and efficacy," said Nimrod Kaufmann , CEO of Inspiro Medical. "This successful study will enable us to move to the next step in the company development and partner with pharmaceutical companies to develop drug-device combinations and also bring better therapy to patients with poor inhalation technique."  

Despite the numerous aerosol delivery devices currently on the market, Inspiro Medical believes that their device can significantly improve effectiveness in deposing the necessary medication. Inspiromatic takes into account drug particle/droplet size; design of the delivery device; and the patient's ability to use and understand the device.

Following this successful trial, Inspiro Medical will continue partnering with global pharmaceutical companies to jointly develop combination products.

Inspiro Medical will be opening investment round A in Q3/2013 to further develop its device and support partnering activities.

Nimrod Kaufmann will present Inspiro's proven technology at BioMed 2013 in Tel Aviv on June 10.

Company contact details:

Nimrod Kaufmann , CEO
Tel: +972-72-260-7051

Media relations:

Efrat Kaduri
Ofir Shpigel Media and Public Relations

SOURCE Inspiro Medical Ltd.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Frost & Sullivan: Standardized Regulations Crucial for Growth in Global Dimensional Metrology Market for Medical Devices
2. Chicago Crime Commission calls on Gov. Quinn to veto medical marijuana bill
3. More Than 100 Winning Medicare Bidders In Maryland Dont Have Proper Licenses To Provide Medical Equipment To Patients
4. Astute Medical, Inc. patrocinerà il simposio informativo presso il meeting sulla nefrologia in terapia intensiva
5. Astute Medical, Inc., veranstaltet Symposium aus anlaß des Critical Care Nephrology Kongress
6. Astute Medical, Inc. va accueillir un symposium éducatif lors dune réunion dédiée à la réanimation néphrologique
7. UBM Canon Celebrates the 30th Anniversary of MD&M East, the East Coasts Largest Medical OEM Event, and the 15th Anniversary of the Medical Design Excellence Awards, the MedTech Industrys Premier Awards Program
8. MAQUET Medical Systems USA Launches LED Concealed Lighting System For Labor, Delivery And Recovery Room
9. Cheetah Medical Announces New Management Team
10. seca Launches the seca mBCA 514 - medical Body Composition Analyzer
11. Kettering Medical Center Acquires Elektas Versa HD Radiotherapy System
Post Your Comments:
(Date:6/23/2016)... , June 23, 2016 Research ... MEMS Devices Medical Market Analysis 2016 - Forecast to 2022" ... The report contains up to date financial data ... analysis. Assessment of major trends with potential impact on the ... analysis of market segmentation which comprises of sub markets, regional ...
(Date:6/23/2016)... INDIANAPOLIS , June 23, 2016 /PRNewswire/ ... Diabetes Tomorrow,s Leaders Scholarship is any indication, the future ... today online at by the Diabetes ... stand in the way of academic and community service ... scholarship program since 2012, and continues to advocate for ...
(Date:6/23/2016)... 23, 2016 Research and Markets ... Volumes: Global Analysis (United States, China, Japan, Brazil, United ... to their offering. ... healthcare business planners, provides surgical procedure volume data in ... with an in-depth analysis of growth drivers and inhibitors, ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... June 27, 2016 , ... TherapySites, the leading ... with Tennessee Counseling Association. This new relationship allows TherapySites to continue ... Association, adding exclusive benefits and promotional offers. , "TCA is extremely excited about ...
(Date:6/26/2016)... Michigan (PRWEB) , ... June 26, 2016 , ... On ... as sponsor of the 2016 Cereal Festival and World’s Longest Breakfast Table in Battle ... honor of the city’s history as home to some of the world’s leading providers ...
(Date:6/25/2016)... ... June 25, 2016 , ... Experts ... applications at AcademyHealth’s Annual Research Meeting June 26-28, 2016, at the Hynes Convention ... health care topics including advance care planning, healthcare costs and patient and family ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, Dr. Omkar Marathe ... from the David Geffen School of Medicine at UCLA. He trained in Internal Medicine ... his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the ...
(Date:6/24/2016)... ... ... Those who have experienced traumatic events may suffer from a complex set of ... or alcohol abuse, as a coping mechanism. To avoid this pain and suffering, Serenity ... event. , Trauma sufferers tend to feel a range of emotions, from depression, guilt, ...
Breaking Medicine News(10 mins):